Two Unanticipated Pregnancies While on Cystic Fibrosis Gene-Specific Drug Therapy
| Autor: | Janet Brown, Leigh Ann Bray, Sigrid Ladores |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pediatrics
medicine.medical_specialty Health (social science) Leadership and Management media_common.quotation_subject Luma Fertility Cystic fibrosis cystic fibrosis Ivacaftor 03 medical and health sciences chemistry.chemical_compound Case Studies 0302 clinical medicine Pharmacotherapy medicine 030212 general & internal medicine reproductive health media_common Reproductive health lcsh:R5-920 Pregnancy business.industry Health Policy Lumacaftor CFTR modulators medicine.disease 030228 respiratory system chemistry pregnancy lcsh:Medicine (General) business medicine.drug |
| Zdroj: | Journal of Patient Experience, Vol 7 (2020) Journal of Patient Experience |
| ISSN: | 2374-3743 2374-3735 |
| Popis: | Women with cystic fibrosis (CF) desire to become pregnant and accomplish the same life goals as women without CF. The underlying pathology of CF and medications used to treat this genetically transmitted disease can affect women’s reproductive potential. An interview with Ana (pseudonym), who became pregnant twice while taking the medication lumacaftor/ivacaftor (LUMA/IVA), was analyzed using thematic analysis. She described her experiences related to “Fertility and Pregnancy Surrounding LUMA/IVA,” the major theme that emerged from her narrative. While there are anecdotal reports of infants conceived by women on LUMA/IVA and other CF precision medications, pregnancy rates and outcomes are not systematically tracked. Education about risks and benefits of these medications should be provided as part of comprehensive clinical care. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|